Abstract
Trabectedin is an FDA-approved DNA minor groove binder that has activity against translocation-associated sarcomas. Lurbinectedin is a next-generation minor groove binder with preclinical activity against myeloid leukemia cells. A dose-finding phase 1 clinical trial was performed in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with further assessment of safety and tolerability. Forty-two patients with relapsed/refractory AML/MDS received lurbinectedin administered as a 1-hour intravenous infusion in a 3 + 3 study design. Two dosing schedules were used: 3.5, 5, 7, or 6 mg on days 1 and 8 or 2, 3, 1, or 1.5 mg for 3 consecutive days on days 1 to 3. Three patients experienced dose-limiting toxicities of rhabdomyolysis (grade 4), hyperbilirubinemia (grade 3), and oral herpes (grade 3) with the day 1 and 8 schedule. Otherwise, adverse events mainly consisted of gastrointestinal manifestations (n = 11), febrile neutropenia/infections (n = 4), pulmonary toxicity (n = 2), and renal failure (n = 2). The most common laboratory abnormalities observed were an increase in creatinine (93%) and anemia, neutropenia, and thrombocytopenia (100%). Overall, 33 of 42 patients (79%) had reduction in blasts in periphe...Continue Reading
References
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Mar 31, 2009·Cancer Treatment Reviews·Xuemei CaiDaniel D Von Hoff
Oct 28, 2010·British Journal of Pharmacology·J F M LealC M Galmarini
May 31, 2011·Molecular Cancer Therapeutics·Daniele G SoaresAnnette K Larsen
Feb 12, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jean-Yves BlaySant P Chawla
Feb 25, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·María Elena ElezMark J Ratain
Jan 23, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ana Teresa AmaralKatia Scotlandi
Sep 16, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George D DemetriShreyaskumar R Patel
Nov 5, 2016·Cancer Research·Matt L HarlowPatrick J Grohar
Nov 23, 2016·Investigational New Drugs·Luis Paz-AresEmiliano Calvo
Jan 10, 2017·Cell·Kaiwei LiangAli Shilatifard
Jan 11, 2017·British Journal of Cancer·Michela RomanoMaurizio D'Incalci
Jan 21, 2017·Investigational New Drugs·Antonio JimenoMark J Ratain
Jul 7, 2017·British Journal of Cancer·Cristina BelgiovineMaurizio D'Incalci
Sep 8, 2017·Immunotherapy·Hiromasa KurodaTadashi Kimura
Sep 30, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E CalvoM Forster
Citations
Jul 12, 2019·Cancer Gene Therapy·Longzhen CuiLin Fu
Oct 24, 2020·Cancers·Adrián Povo-RetanaLisardo Boscá
Mar 20, 2021·Future Oncology·Javier BaenaLuis Paz-Ares
Jun 3, 2021·Cancers·Dario P AnobileChiara Riganti
Aug 21, 2021·Bioorganic & Medicinal Chemistry·Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza